BOARD-ADVISORS-AG
3.11.2021 11:22:10 CET | Business Wire | Press release
LEA Partners GmbH (LEA), a private equity and venture capital investor based in Karlsruhe, Germany, today announced the acquisition of Base-Net Informatik AG (Base-Net), a Swiss software provider leading in the field of credit and mortgage management.
Board Advisors Deutschland AG acted as the exclusive M&A advisor to the shareholders of Base-Net. The team of Christoph Löslein, Urs Niederberger, Felix Brokatzky and Federico Arcelli was able to successfully complete the transaction in less than five months.
"I am extremely pleased that, through the efforts of Board Advisors, we were able to find a new majority shareholder that is equally beneficial to the customers and employees of Base-Net Informatik AG. Despite a complex transaction structure, the advisors of Board Advisors had the mandate under control at all times, were able to successfully complete the project in a record-breaking time and to the full satisfaction of the shareholders."
Stefan Hermann, Founder and Chairman of the Board of Base-Net Informatik AG
Base-Net, headquartered in Sursee in the canton of Lucerne, was founded in 1994. With its WinCredit software it is the leading Swiss software provider in the field of credit and mortgage management. Currently, over 400 banks, insurance companies, pension funds and financial intermediaries use the company's software. In addition, Base-Net develops and operates a state-of-the-art platform for credit and mortgage refinancing.
"The market for credit management software is continuously growing and is highly attractive for us. Therefore, we are very pleased to have gained Base-Net, another leading and long-established company, for us. With this, we are taking another step in building a leading financial services platform in the DACH region."
Philipp Hertel, Partner at LEA
About Base-Net
Base-Net is the leading Swiss software provider in the field of credit and mortgage management. In addition to its loan management software, its solutions for refinancing and exchanges with the Swiss Pfandbriefbank are among the standard solutions in the Swiss financial sector. Founded in 1994 and based in Sursee, the company now serves around 400 banks and insurance companies. For more information, please visit www.basenet.ch .
About LEA Partners
LEA Partners is an entrepreneurial equity partner supporting founders and management teams in different stages of development to grow and achieve a leading market position. Based in Karlsruhe, one of the largest technology clusters in Europe, LEA Partners has managed investments in numerous technology companies since 2002. Following the merger of PROCAD, keytech and ACATEC in May 2021 and that of TAIFUN, M-Soft and PinnCalc in October 2021, the establishment of a buy-and-build platform in the financial services sector, which already includes the b+m Group in addition to Base-Net Informatik AG, represents the next significant transaction for the LEA B2B Tech funds focused on software companies from the DACH region. For more information, please visit www.leapartners.de .
About Board Advisors
Board Advisors is a Management Consulting and M&A advisory firm founded in 2005 by Christoph Löslein and is today headquarted in Freiburg im Breisgau. Board Advisors currently has own operations in Berlin, Zurich, Sursee, Basel, Nice, Munich and Manchester and has a network of international cooperation partners.
Board Advisors has in-depth expertise in the health and technology sectors and has successfully completed numerous business development projects, buy- & sell-side transactions and fundraising mandates in recent years. For further information, please visit www.boardadvisors.de .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211103005562/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom